Salarius Pharmaceuticals, Inc.

NASDAQ (USD): Salarius Pharmaceuticals, Inc. (SLRX)

Last Price

1.41

Today's Change

-0.04 (2.75%)

Day's Change

1.41 - 1.45

Trading Volume

24,256

Overview

Market Cap

2 Million

Shares Outstanding

1 Million

Avg Volume

350,189

Avg Price (50 Days)

1.57

Avg Price (200 Days)

3.03

PE Ratio

-0.16

EPS

-8.73

Earnings Announcement

13-Nov-2024

Previous Close

1.45

Open

1.45

Day's Range

1.41 - 1.45

Year Range

1.26 - 7.272

Trading Volume

24,256

Price Change Highlight

1 Day Change

-2.76%

5 Day Change

-3.42%

1 Month Change

-0.70%

3 Month Change

-28.06%

6 Month Change

-64.03%

Ytd Change

-72.46%

1 Year Change

-75.52%

3 Year Change

-99.07%

5 Year Change

-99.82%

10 Year Change

-100.00%

Max Change

-100.00%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment